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2+, 3+. States: A feature selection is executed by a modeler who decides which set 
of features describes a disease state or patient cohort best. For identifying the most 
relevant attribute combinations a cluster analysis is applied beforehand. Transitions: 
Patients remain in one particular state as long as they match the predetermined 
features and attributes. Otherwise, a change to another state occurs. Thereby, a 
sequence of states for each patient is defined. As a final step, these sequences are 
used for deriving a model structure. ExpEctEd REsults: Markov models backed up 
by real-life patient records. As a result of the automatic generation process models 
can be used for validating hypotheses or comparing outcomes for different patient 
cohorts. Therefore, the usage of such models is not strictly limited to health eco-
nomic analysis. A first validation indicates the feasibility of the outlined methods. 
It was possible to reconstruct a published disease model. conclusions: Ongoing 
research is conducted with focus on data quality, i.e., accuracy, completeness and 
timeliness, at the regional cancer registry.
PRM148
Continuous Patient engageMent in CoMPaRative effeCtiveness 
ReseaRCh (CeR): an aPPliCation in CaRdiovasCulaR disease (Cvd)
Vandigo J., Oloyede E., Abdulhalim A.M., Mullins C.D.
University of Maryland School of Pharmacy, Baltimore, MD, USA
objEctivEs: A 10-step, systematic framework to enhance patient engagement 
throughout the CER process has been previously proposed. The objective of this 
research was to apply this framework in the context of CVD since CVD is the 
leading cause of death in the United States and impacts a diverse patient popu-
lation. MEthods: At each of the 10 steps in the research process, the rationale 
and means for researchers to engage CVD patients is presented. REsults: When 
prioritizing CER topics, patients can inform whether resources should be allocated 
towards hypertension, a highly prevalent disease with various established thera-
peutic options, or into finding new treatment options for patients affected by pul-
monary arterial hypertension, a rare disease. Patients with CVD can also help to 
select outcomes that are meaningful from their perspective. Interest in the major 
outcomes (stroke, heart failure) will likely be balanced against patient concerns 
with treatment side effects, such as dizziness and dry cough, which can impact 
quality of life. In the latter steps of translation and dissemination, patients can 
help to tailor results under primary, secondary, or tertiary prevention and across 
racial/ethnic subgroups. conclusions: The 10-step framework can be tailored 
to engage patients with CVD. For some stages of CER, purposes and strategies for 
patient engagement for CVD are similar to many other disease states. However, 
there are unique best practices for patient engagement in CVD. Researchers should 
recognize that there is no “one-size-fits-all” approach to patient engagement and 
should engage CVD patients throughout the CER continuum.
PRM150
value of RaRe disease non-inteRventional studies to suPPoRt PayeR 
& CliniCal desCision Making
Degun R., Patel D., Marinsek N., Chalmers M.
Navigant, London, UK
objEctivEs: In rare diseases and sub-populations for specialty diseases, national 
and regional payer negotiations regarding funding and reimbursement of new 
drugs can be challenging due to the lack of available robust data to inform deci-
sion making. Clinical trials designed to ensure regulatory approval often lack the 
necessary information to meet the needs of a diverse range of payer and clinical 
stakeholders across the globe. Traditional patient registries, if available, generally 
do not capture the required level of detail, especially in terms of health-economic 
data. To ensure ongoing access, new therapies to treat rare diseases require further 
real world evidence to build a strong clinical and economic case for long term 
treatment provision. MEthod: We employed a variety of traditional and innova-
tive methods to collect real-world evidence on disparate populations of patients 
with rare diseases. Retrospective chart review studies have been conducted to 
understand demographics, clinical and pathological characteristics, treatment, 
outcomes and resource use. Patient and caregiver surveys have subsequently been 
used to correlate quality of life, functional status and economic burden to patient 
treatment pathways. REsults: Non-interventional studies provided a longitudi-
nal understanding of patient care pathway from diagnosis to long-term treatment 
and follow-up including the natural history of a rare disease, genotypic/phenotypic 
variability, differences in treatment patterns across countries and the clinical drivers 
of therapy use. This enabled comparison of real-world treatment practice versus 
clinical guidelines. In addition, direct and indirect costs were calculated to under-
stand the budget impact of treatment. Insights helped the manufacturer refine the 
product value proposition and provide necessary evidence to support product access 
and reimbursement. conclusions: Rare disease non-interventional studies offer 
manufacturers the opportunity to fulfill peri and post-launch evidence needs of 
regulators and payers by providing bespoke and robust real world data efficiently.
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PubliCation of MethodologiCal guidelines: the develoPMent of 
systeMatiC Reviews (sR) and Meta-analyses of RandoMized CliniCal 
tRials by the dePaRtMent of sCienCe and teChnology of the 
bRazilian MinistRy of health (deCit/Moh)
Elias F.T.S.1, Koury C.D.N.2
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Since 2004, DECIT supports the production of SR by teaching and research institu-
tions in Brazil. However, these studies were guided by international recommenda-
tions causing some variability in the execution and presentation of results. In order 
to standardize and equalize the elaboration quality of SRs throughout Brazil, DECIT 
requested to research institute Hospital do Coração Hcor draft this guideline. The 
initiative was funded by the Support Program for the Institutional Development of 
the Brazilian Public Health System. The guideline was based on two international 
and truncating the analysis. REsults: The survival outcomes produced by the 
model are presented graphically to illustrate the impact of the different methods, 
along with the magnitude of change in the incremental benefits and the resulting 
incremental cost-effectiveness ratios (ICERs) using the various methods compared 
to the standard approach. Conclusion: Capturing and quantifying the structural 
uncertainty in partitioned survival analysis is not well developed in the literature. 
This study demonstrates the considerable uncertainty and the potential for bias 
from choosing one method of extrapolating outcomes for an economic evaluation 
using a partitioned survival analysis. The study also proposes options for exploring 
the uncertainty in order to present a balanced analysis and avoid bias in economic 
evaluations for oncology research.
PRM145
the Challenges of Pilot testing tRanslated PRo MeasuRes with 
ChildRen
Two R.1, Currie D.1, Browning R.1, Loten M.1, Herdman M.2
1PharmaQuest Ltd, Banbury, UK, 2Insight Consulting & Research, Mataró, Spain
intRoduction: PRO measures aimed at child respondents are generally devel-
oped with the input of children from the target population, although in certain 
cases their age or medical condition can have implications that make this less 
feasible. This extends also to the translation and linguistic validation of these 
measures, where the usual standard of pilot testing translations with the target 
population may not be appropriate or beneficial. This presentation investigates 
the challenges of pilot testing translations with children, and explores alternative 
validation methods. bAckgRound: Current guidelines advise that translated PRO 
measures should be tested with patients from the target population to best assess 
the measures’ suitability. From our own findings, pilot testing with children can 
be very successful as they give more creative answers during cognitive interviews, 
and they can be more willing to give open, honest answers than adults. However, 
the success of pilot testing with children can vary depending on their age. Younger 
children may have too limited a vocabulary to express concepts in their own words, 
or may struggle to understand the cognitive debriefing process. Additionally, in 
some circumstances there may be ethical issues involved when asking ill children 
to decide whether to participate in this process which may be difficult for them to 
understand. AltERnAtivEs: Alternative methods must aim to establish the same 
information that would be obtained from the target population: i.e., whether the 
translation is appropriate for that group. Therefore we propose review processes 
involving parents, teachers, paediatric nurses or clinicians, depending on the meas-
ure’s content and target age range. conclusion: In some cases it is possible to 
successfully pilot test translated PRO measures with children, and it can be the 
optimum solution, where practical. However, reviews by parents or suitably quali-
fied professionals are useful alternatives where testing with children might not 
be feasible.
PRM146
Quantifying the iMPaCt of PRogRession on suRvival in onCology: 
an aPPliCation of statistiCal Modeling fRaMewoRk to MeasuRe the 
iMPaCt of events on subseQuent Risks
Ishak K.J., Proskorovsky I.
Evidera, St-Laurent, QC, Canada
In many diseases, the occurrence of a clinical event (e.g., stroke) can change the 
risk of other, usually more serious, events (e.g., death). Quantifying the impact of 
the first event and factoring this into assessment or extrapolation of the risk of the 
second event is important for clinical understanding of the disease as well as health 
economic assessments of new treatments. For instance, in oncology, understanding 
the impact of progression of disease on the risk of dying can be vital for projection of 
overall survival, which is often only partially observed in trials. Proper understand-
ing of the impact of the event requires consideration of not only the occurrence of 
the event, but also its timing and the possibility that its effect changes with time 
following the event. For instance, patients who progress early after initiation of 
treatment may be subject to a greater increase in risk of death than a patient who 
progresses, say, a year after treatment. Similarly, once progressed, the increase in 
mortality may be highest soon after the event and gradually decline among surviv-
ing patients. We will outline a statistical modeling framework designed to quantify 
these various dimensions of the impact of events using Cox regression models 
with time-dependent covariates and effects (i.e., coefficients) to reflect the timing 
of event (TE) as well as time elapsed since the event (TSE). The model produces 
estimates that have direct clinical relevance; for instance, the coefficient for TE 
provides an assessment of the benefit of delaying progression, while TSE reflects 
whether and for how long the increase in mortality is sustained and whether it 
ever returns to the level of patients who had not progressed. The parameterization 
of the model will be illustrated with example code and analyses of example data.
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autoMatiC CReation of disease Models using data Mining 
teChniQues on data fRoM a CliniCal CanCeR RegistRy
Pobiruchin M.1, Bochum S.2, Martens U.M.2, Kieser M.3, Schramm W.1
1Heilbronn University, Heilbronn, Germany, 2SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany, 
3University of Heidelberg, Heidelberg, Germany
objEctivEs: Health economic disease models are often build with data from clinical 
trials and thus do not necessarily reflect the routine care situation in hospitals. For 
this scenario, we outline a method to generate disease models using data mining 
algorithms on patient records from a regional clinical cancer registry. MEthods: 
Markov models are a common technique in decision making. Their structure of 
states and transitions reflects the progress of a disease. We define a disease state as 
a set of features which represents a specific state of illness, e.g., diagnosis of breast 
cancer in HER-2-positive (human epidermal growth factor receptor 2) women who 
are treated with chemotherapy and mastectomy. In particular, a feature can consist 
of several attributes, e.g., HER-2 status can be described with the attributes 0, 1+, 
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surveillance data collection. Such are defined as an aircraft without a human pilot 
on board, operated either autonomously by computer or under remote control by 
a human pilot. MEthods: We performed a targeted literature search for medi-
cal applications of UAS and rank-ordered strengths and weaknesses according to 
emerging applications and corresponding difficulty, feasibility and cost. REsults: 
Based on secondary sources, we report conceptual factors that can contribute to the 
practicality and efficiency of UAS in emergency medical situations. These were 1) 
frequency of occurrence, 2) time-sensitivity of occurrence, 3) rurality and complex 
terrain, 4) financial impact and 5) cultural acceptance. The results of our matrix 
point to a gradation of accepted uses for UAS with the variance in geographical 
location and urgency directly relating to an increase in operation costs. It is well 
known that natural disasters are increasing in frequency and intensity. Salient 
platforms for using UAS in medical delivery would be in the areas of natural and 
combative disaster relief. During these occurrences the use of UAS to aid in the 
medical relief could be a great asset. conclusion: Our model illustrates how Big 
Data can be leveraged to improve ongoing quality and efficiency of UAS-delivered 
medical supplies, reduce time for delivery of supplies during times of natural dis-
asters, and thus eschew our reliance on manned aircraft to assist in critical and 
non-critical medical operations.
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PubliCation Manual of budget iMPaCt analysis (bia) by the 
dePaRtMent of sCienCe and teChnology of the MinistRy of health 
(deCit)
Koury C.D.N.1, Elias F.T.S.2
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The epidemiological and economic methods applied to health technologies evalu-
ations had a significant development in the last two decades. The need to balance 
the incorporation of new technologies in health care and limited financial resources 
promoted the construction and application of instruments supporting the decision 
making of health technology. The requirement Budget Impact Analysis formally 
stated in Law 12.401/2011 establishing the incorporation process technologies in 
SUS. In this context, in 2010/2011, the National Agency of Sanitary Surveillance 
(ANVISA) and DECIT, in partnership Institute for Health Technology Assessment 
(IATS) for drawing up of this guideline. In the first stage of development were 
used international recommendations of Canada, Australia, the UK and Poland, 
the recommendations of the International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) and the methods used in studies of budgetary impact 
that had already been published. Afterwards, drafted a preliminary version of the 
Guideline and a standard tool - Excel worksheets - to estimate the uptake of mon-
etary resources required for adoption of new technologies. Revisions were carried 
out by technicians DECIT and health agencies, and the proposal was submitted to 
the Working Group on Development of Methodology REBRATS, composed of experts 
and academic researchers from several Brazilian states. Were also carried out work-
shops for the application of spreadsheets. In 2012, the first edition of the Guidelines 
was published two thousand copies in Portuguese in order to provide best practice 
recommendations for studies of budget impact.
PRM157
Mixed Methods foR the develoPMent of ClinCial outCoMe 
assessMents (Coas): exPloRing fuRtheR Possibilities foR Mixed data 
ColleCtion and analysis
Willgoss T.G.1, Humphrey L.1, Symonds T.2, Cappelleri J.C.3
1Abacus International, Manchester, UK, 2Pfizer Ltd, UK, 3Pfizer Global Pharmaceuticals, New York, 
NY, USA
Mixed methods are fast becoming the go-to methodology for the development and 
validation of clinical outcome assessments (COAs). Although mixed methods have 
become popularized for COA development, most of this attention has focussed on 
Rasch measurement theory (RMT). However, the potential utility of mixed methods 
in COA development goes beyond RMT. There is a well-established literature base 
exploring the use of mixed data collection and crossover analyses in social research 
and many of these approaches can be readily applied to COA development. Thus a 
toolkit of methods is proposed which can be pragmatically selected to support the 
development of interpretable and purposeful COAs. Further integration of qualita-
tive and quantitative data throughout the COA development process can serve to 
continually test the evolving hypothesis of the measurement construct and aid 
in evidence triangulation. Data can be transformed to create new data through 
‘quantitizing’ qualitative data and ‘qualitizing’ quantitative data. Qualitative data 
collected during concept elicitation can be converted into binary code allowing 
development of inter- and intra-respondent matrices to explore the frequency 
and intensity of concepts. These data can be subjected to factor, correlational and 
regression analyses to explore the hierarchical structure and inter-relationships of 
qualitatively-derived themes and variables. Concept mapping techniques also allow 
the translation of qualitative data into pictorial form to show “clusters” of, or inter-
relationships between, concepts. This collaborative approach involves stakeholders 
as partners in the research to generate, sort and rate items into conceptual models 
using statistical analyses. There are exciting opportunities to build upon existing 
practice and advance mixed research approaches in the field of COA development. 
Integrating mixed data collection and crossover analyses can enhance the interpret-
ability and purposefulness of COAs ensuring they are developed with an evolving 
hypothesis and fit for purpose. The application of such methods for regulatory COA 
development requires further exploration.
PRM158
siMultaneous iteM develoPMent (sid) foR CliniCal outCoMes 
assessMents (Coas)
Humphrey L., Willgoss T.G.
Abacus International, Manchester, UK
guidelines used in clinical research: The Cochrane Reviewer’s Handbook and a guide-
line prepared by the The Australian National Health and Medical Research Council. 
The aim of the guideline was to introduce the main concepts through a language 
that is more simple and accessible to health care professionals, familiar or not with 
the methodology of systematic reviews and meta-analyses. This guideline covers 
the three phases of a SR: planning, production and reporting of the SR. It does not 
take into account the impact of the type of question in the review process and does 
not exhaust all the mechanisms necessary in order to understand and perform a 
meta-analysis. It also presents the detailing of some fundamental concepts needed 
to conduct the systematic review in the form of appendices. In 2011, it was given the 
first version of the guideline. DECIT was responsible for the review and publishing 
of the final document. In 2012, the first issue of the guideline was published. The 
importance of the guideline is to orient and standardize the preparation and pro-
duction of a quality SR, mainly due to the gap that exists in the national literature.
PRM152
ColleCting PRos in Patient RegistRies: the need foR and Potential 
iMPaCt of PRoviding PRo data to the tReating PhysiCian – and when
Gemmen E.1, Leavy M.B.2
1Quintiles Real World & Late Phase, Rockville, MD, USA, 2Quintiles Real World & Late Phase, 
Cambridge, MA, USA
The advent of ePROs and direct-to-patient reporting has enabled patients participat-
ing in registries to report their symptom or treatment experiences between physi-
cian visits, with minimal patient burden. These independent reporting approaches 
are often used to support patient retention over long follow-up periods, and/or to 
collect patient-reported data outside of typical physician visit schedules. When a 
patient completes PROs independent of a physician’s presence (i.e., not completed 
at the physician’s office and not entered by the registry site), the treating physician 
may not be aware of the patient’s responses and may need to either proactively 
ask for this information or wait to obtain this information at the end of the study. 
The move toward independent reporting of PRO data introduces several competing 
concerns. First, physician knowledge of the PRO responses could potentially alter 
the naturalistic follow-up in an observational study, if, for example, the physician’s 
knowledge of the PRO response prompts him/her to alter the patient’s treatment. 
As a result, patient reporting independence may be preferred from a research purity 
perspective. However, any PRO response that may be a safety signal would carry 
ethical considerations; in such a case, reporting independence would not be pre-
ferred. If patient care is always paramount to the benefits of research, then it could 
be argued that the optimization of patient care is only possible when the physician 
has all available patient information (e.g., PROs) at his/her disposal, in as close to 
real-time as possible. In addition, some research indicates that patients are more 
likely to complete PROs when their physician is aware of and using the PRO data to 
inform treatment decisions. Further discussion will focus on sponsor and researcher 
responsibilities for funneling observed data on a patient’s experience back to the 
treating physician, drawing on examples from the literature and registry protocols.
PRM153
PRaCtiCal aPPRoaChes to aChieving Real-woRld study data 
RePResentative of the taRget PoPulation
Gemmen E.1, Parmenter L.2, Mendelsohn A.B.1
1Quintiles Real World & Late Phase, Rockville, MD, USA, 2Quintiles Real World & Late Phase, 
Reading, UK
puRposE: To describe the most effective approaches to achieving a real-world 
study data sample that is representative of the target population. dEscRiption: 
Considerable attention is paid to the design and analysis of outcomes research 
studies to address internal validity by minimizing bias and confounding. However, 
too often, study sample populations are simply assumed to be representative of 
the study populations from which they are drawn, or are assessed for their repre-
sentativeness only after the study has been conducted. Ideally, sample estimates 
should be as close as possible to their population value in order to make inferences 
about that study population. Practical implementation of measures to avoid selec-
tion bias and ensure a robust sampling procedure can be problematic. Challenges 
include, willingness of sites and patients to participate in research (convenience 
sampling), and management of site and patient drop-out after the study has begun. 
While many database studies and patient registries carry very large sample sizes 
and therefore begin to approximate the target population simply by means of 
sheer size, smaller studies may need to take steps, through stratified sampling 
and enrollment caps, to ensure that the study sample is reflective of the target 
population. These stratification variables may be at the site level (e.g., physician 
specialty, geography), the patient level (age, gender, ethnicity, disease duration) or 
both. Temporal issues may also be problematic where studies performed in the past 
may not reflect rapid changes impacting today’s target population. Following a brief 
overview of the design and analysis considerations, this presentation will focus on 
case examples, drawn from different organizations, of approaches to achieving a 
representative sample, highlighting some of the challenges intrinsic to real-world 
research. Best practice recommendations will be provided to guide researchers on 
the most effective approaches, including the use of reference populations within 
specific countries.
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utilization of unManned aiRCRaft systeMs (uas) foR eMeRgenCy 
MediCal situations in RuRal CoMMunities: a vision foR the futuRe
Spitsberg R.1, Jones C.2
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objEctivE: We propose a paradigm and ranking system for potential medical 
applications of unmanned aircraft systems (collectively UAS). Over the past three 
decades, UAS have become a vital component to our armed forces, used notably 
for combat but also commonly used for work in intelligence, reconnaissance and 
